SEC Comment Letter 0000000000-24-002306 to Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287) (ALLO)
Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287)
Date: Feb. 29, 2024 · CIK: 0001737287 · Accession: 0000000000-24-002306
AI Filing Summary & Sentiment
File numbers found in text: 001-38693
Letter
United States securities and exchange commission logo February 29, 2024 David Chang President and Chief Executive Officer Allogene Therapeutics, Inc. 210 East Grand Avenue South San Francisco, California 94080 Re:Allogene Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-38693 Dear David Chang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
February 29, 2024
David Chang
President and Chief Executive Officer
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, California 94080
Re:Allogene Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed February 28, 2023
File No. 001-38693
Dear David Chang:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences